دورية أكاديمية

Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival.

التفاصيل البيبلوغرافية
العنوان: Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival.
المؤلفون: Lopes, M H, Santos, T G, Rodrigues, B R, Queiroz-Hazarbassanov, N, Cunha, I W, Wasilewska-Sampaio, A P, Costa-Silva, B, Marchi, F A, Bleggi-Torres, L F, Sanematsu, P I, Suzuki, S H, Oba-Shinjo, S M, Marie, S K N, Toulmin, E, Hill, A F, Martins, V R
المصدر: Oncogene; 6/18/2015, Vol. 34 Issue 25, p3305-3314, 10p, 1 Chart, 5 Graphs
مصطلحات موضوعية: GLIOBLASTOMA multiforme, PRIONS, HSP70 heat-shock proteins, NERVOUS system, ASTROCYTOMAS, PHOSPHOINOSITIDES, PHOSPHATIDYLINOSITOL 3-kinases, GENE knockout, DIAGNOSIS
مستخلص: Glioblastomas (GBMs) are resistant to current therapy protocols and identification of molecules that target these tumors is crucial. Interaction of secreted heat-shock protein 70 (Hsp70)-Hsp90-organizing protein (HOP) with cellular prion protein (PrPC) triggers a large number of trophic effects in the nervous system. We found that both PrPC and HOP are highly expressed in human GBM samples relative to non-tumoral tissue or astrocytoma grades I-III. High levels of PrPC and HOP were associated with greater GBM proliferation and lower patient survival. HOP-PrPC binding increased GBM proliferation in vitro via phosphatidylinositide 3-kinase and extracellular-signal-regulated kinase pathways, and a HOP peptide mimicking the PrPC binding site (HOP230-245) abrogates this effect. PrPC knockdown impaired tumor growth and increased survival of mice with tumors. In mice, intratumor delivery of HOP230-245 peptide impaired proliferation and promoted apoptosis of GBM cells. In addition, treatment with HOP230-245 peptide inhibited tumor growth, maintained cognitive performance and improved survival. Thus, together, the present results indicate that interfering with PrPC-HOP engagement is a promising approach for GBM therapy. [ABSTRACT FROM AUTHOR]
Copyright of Oncogene is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:09509232
DOI:10.1038/onc.2014.261